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Abstract
Background: Bone is the predominant site of metastasis from breast cancer, and recent trials have demonstrated that 
adjuvant bisphosphonate therapy can reduce bone metastasis development and improve survival. There is an unmet need 
for prognostic and predictive biomarkers so that therapy can be appropriately targeted.
Methods: Potential biomarkers for bone metastasis were identified using proteomic comparison of bone-metastatic, lung-
metastatic, and nonmetastatic variants of human breast cancer MDA-MB-231 cells. Clinical validation was performed 
using immunohistochemical staining of tumor tissue microarrays from patients in a large randomized trial of adjuvant 
zoledronic acid (zoledronate) (AZURE-ISRCTN79831382). We used Cox proportional hazards regression, the Kaplan-Meier 
estimate of the survival function, and the log-rank test to investigate associations between protein expression, clinical 
variables, and time to distant recurrence events. All statistical tests were two-sided.
Results: Two novel biomarker candidates, macrophage-capping protein (CAPG) and PDZ domain–containing protein GIPC1 
(GIPC1), were identified for clinical validation. Cox regression analysis of AZURE training and validation sets showed that 
control patients (no zoledronate) were more likely to develop first distant recurrence in bone (hazard ratio [HR] = 4.5, 95% 
confidence interval [CI] = 2.1 to 9.8, P < .001) and die (HR for overall survival = 1.8, 95% CI = 1.01 to 3.24, P = .045) if both proteins 
were highly expressed in the primary tumor. In patients with high expression of both proteins, zoledronate had a substantial 
effect, leading to 10-fold hazard ratio reduction (compared with control) for first distant recurrence in bone (P = .008).
Conclusions: The composite biomarker, CAPG and GIPC1 in primary breast tumors, predicted disease outcomes and benefit 
from zoledronate and may facilitate patient selection for adjuvant bisphosphonate treatment.
The skeleton is the predominant site for metastasis in breast 
cancer, providing a fertile microenvironment for survival and 
growth of disseminated tumor cells. Bone-targeted agents 
such as bisphosphonates and denosumab, which disrupt the 
destructive interactions between cancer and bone cells, are 
widely used to prevent skeletal complications of bone metas-
tasis but have also been investigated as adjuvant agents 
to prevent or delay bone metastasis. Several large trials of 
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adjuvant bisphosphonate therapy in early breast cancer have 
now reported (1–3), including the open-label, multicenter, phase 
III AZURE trial (BIG01/04 - ISRCTN79831382), which recruited 
3360 patients with stage II/III breast cancer randomized (1:1) to 
standard adjuvant therapy alone (control) or standard therapy 
with zoledronic acid (zoledronate) (19 doses of 4 mg in 5 years) (1). 
After a median of 84 months follow-up, for the whole trial popu-
lation, although there was no statistical difference in disease-
free survival, zoledronate reduced bone metastases (adjusted 
hazard ratio [HR] = 0.78, 95% confidence interval [CI] = 0.63 to 
0.96, P = .020). Moreover, in a preplanned analysis, zoledronate 
improved disease outcomes for women (n  =  1041) who were 
more than five years postmenopausal at diagnosis (adjusted HR 
for invasive disease-free survival = 0.77, 95% CI = 0.63 to 0.96) 
(4). Furthermore, a meta-analysis of individual patient data in 
17 791 women from 22 randomized trials confirmed that in post-
menopausal women adjuvant bisphosphonates reduced bone 
recurrences and breast cancer death by 34% (P < .001) and 17% 
(P = .004), respectively (5). These studies are likely to be practice 
changing but also highlight the unmet need for biomarkers to 
identify patients at risk of bone metastasis to guide selection for 
adjuvant bisphosphonate treatment.
In the past decade, multiple gene expression datasets from 
analysis of breast cancer metastasis have identified key path-
ways underlying determinants of metastasis and provided 
information on which genes drive metastasis to specific organs, 
including the skeleton (6–11). Proteomic approaches also have 
high potential for the development of biomarkers for prediction 
of metastasis development (12).
In this study, we have identified novel bone metastasis-asso-
ciated biomarkers from proteomics studies in cell lines, veri-
fied the increased expression of these proteins in bone homing 
cells, and carried out clinical validation in large training and 
independent validation sets on tissue microarrays (TMAs) from 
patients in the AZURE study, leading to a clinically validated 
composite biomarker with both prognostic and predictive utility.
Methods
Proteomic Analysis and Identification of Candidate 
Biomarkers
Metastatic variants of the human breast cancer cell line 
MDA-MB-231 home to bone (BM1, BM2) or lung (LM), when 
administered intravenously to nude mice, whereas the ‘paren-
tal’ MDA-MB-231 cells (PCC) do not (8,13). We explored dif-
ferences in the proteomes of BM1, BM2, LM, and PCC cells to 
identify differentially regulated proteins specifically associated 
with development of bone metastases in human breast cancer. 
Figure  1 indicates the key steps in our approach for the prot-
eomic discovery of novel biomarkers.
Differential protein expression between multiple independ-
ent cultures of these cell lines was quantified using two-dimen-
sional difference gel electrophoresis (2D-DIGE) (14). Following 
analysis of the 2D-DIGE gels, gel spots of interest were excised 
manually from silver-stained DIGE gels, and tryptic peptides 
were generated for mass spectrometric analysis using an in-
gel digestion method. Proteins were identified using nano–liq-
uid chromatography/mass spectrometry/mass spectrometry 
(LC/MS/MS) analysis on a QSTAR XL quadrupole time-of-flight 
hybrid mass spectrometer (AB Sciex, Warrington, UK) coupled 
online with an Agilent 1100 Series nano-LC System (Agilent 
Technologies, Berkshire, UK) through electrospray ionization. 
The MS/MS raw data files from the LC/MS/MS analysis were pro-
cessed by Analyst v2.0 and a script plug-in Mascot.dll 1.6b24 (AB 
Sciex, Warrington, UK) then sent to the local Mascot database 
search engine (v2.3, Matrix Science, Boston, MA).
Proteins with statistically significantly higher expression 
relative to PCC cells and greatest fold-change in the bone meta-
static cell lines (fold changes ≥ 2, P =  .029 by Wilcoxon-Mann-
Whitney test), but not with higher expression in the LM cells, 
were assessed for relevance in cancer and/or bone metastasis 
using published literature and verified by western blotting. 
Figure 1. Simplified flow diagram showing key proteomic steps used for discovery of novel biomarkers for risk of bone metastasis development. Proteins extracted 
from multiple independent cultures of cell lines were labeled using Cy5 fluorescent dye while an internal standard was labeled with Cy3. Separation of proteins (by 
isoelectric point and molecular weight) and image capture (fluoresence densitometry) creates protein array images that can be compared so as to detect differential 
protein expression between cell line types and replicates (intensity of fluoresence). Proteins of higher expression in bone-homed cell lines were excised from silver-
stained two-dimensional difference gel electrophoresis gels, reduced to peptides, and analyzed using tandem mass spectrometry. Identified proteins were assessed for 
known/reported relevance to breast cancer and/or bone metastasis prior to selection for validation of expression on breast cancer tissue microarrays. 2D-DIGE = two-
dimensional difference gel electrophoresis; IHC = immunohistochemistry; LC/MS/MS = liquid chromatography/mass spectrometry/mass spectrometry; TMA = tissue 
microarray.
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Further details are available in the Supplementary Materials 
(available online).
Clinical Validation of Potential Biomarkers of Bone 
Metastasis Risk
Patients and Samples
All analyses on patient samples were performed with Ethics 
approval and informed patient consent. Initially, protein expres-
sion of target molecules was characterized using a local TMA 
constructed from 364 breast cancer samples graded 1, 2, and 
3 (Data Supplement, available online). The main patient-based 
analyses were then performed on TMAs constructed from pri-
mary tumors from patients recruited into the AZURE trial (1). 
This provides an excellent resource for validation of protein bio-
markers emerging from our proteomics studies because of the 
relatively high prevalence of bone metastatic outcomes and long 
follow-up (median  =  84  months, interquartile range  =  66–93). 
Triplicate cores of breast tumor tissue were arrayed across repli-
cate TMAs for immunohistochemistry.
Immunohistochemistry
Protein expression was assessed on TMAs using immunohis-
tochemistry (15,16). Briefly, 5  µm serial sections of TMA were 
dewaxed in xylene and rehydrated through graded alcohols. 
Endogenous peroxidases were blocked (3% H202, 10 minutes), 
and antigens retrieved by microwaving slides. After cooling 
and washing, slides were blocked with goat serum (1:10; Zymed 
antibody diluent; 20 minutes), after which primary antibodies 
were applied (overnight, 4°C). Details of primary and secondary 
antibodies are presented in Supplementary Table  9 (available 
online). Following washing and incubation with HRP-conjugated 
secondary antibodies, proteins were visualized using diamin-
obenzidine before counterstaining with haematoxylin, dehydra-
tion, and mounting.
A three-tier ordinal categorical system was used to rank 
the tumors based on intensity of cytoplasmic staining (15,16), 
where 1 = weak staining; 2 = moderate, easily perceived stain-
ing; 3  =  strong/intense staining; ie, the scoring was based on 
staining intensity only and not on percentage of positivity 
(Supplementary Materials, available online). In analyses, for 
simplification, the term ‘high’ refers to a staining score of 3, 
and ‘low’ to scores of 1 or 2. Cytoplasmic staining scores were 
assessed independently by two trained operators, blinded to 
outcome data, under the supervision of an experienced histo-
pathologist (AMH), who also adjudicated discrepant scores and 
the level of agreement of the two scores was measured using 
Cohen’s kappa coefficient.
Statistical Analyses
Statistical analyses followed REMARK guidelines (17) and tested 
the associations between protein expression and all relevant 
clinical and pathological variables available (eg, estrogen recep-
tor [ER]/progesterone receptor [PR]/human epidermal growth 
factor receptor 2 [HER2] status) using Fisher’s Exact test for 
categorical variables and the Kruskal-Wallis test (for continu-
ous variables) (18), before assessing associations with time-to-
event data (time to first distant recurrence, time to first skeletal 
recurrence, time to first nonskeletal recurrence) using Cox pro-
portional hazards regression, the Kaplan-Meier estimate of the 
survival function, and the log-rank test. Time to first distant 
recurrence was defined as the time from the date of random 
assignment to the date of the distant recurrence. In analyses, 
other types of events were censored; eg, if a local recurrence 
occurred prior to any distant recurrence, the patient would be 
censored at the date of the local recurrence. Time to first skeletal 
recurrence and first nonskeletal recurrence were defined simi-
larly. Time to first skeletal recurrence irrespective of all other 
previous recurrences was also investigated.
Time-to-event analysis was first performed within treat-
ment arms to identify any prognostic effects related to the bio-
markers. Subsequently, similar analyses were performed for the 
treatment effect within subgroups defined by biomarker status 
to assess predictive effects of the biomarker. The predictive het-
erogeneity of effect between treatment arms for time to distant 
events was assessed in multivariable analysis by including an 
interaction term in the Cox proportional hazard regressions 
for treatment arm and biomarker (while adjusting for systemic 
therapy plan, ER status, and lymph node involvement). All sta-
tistical tests were two-sided.
Results
Proteomic Studies, Selection of Proteins for Further 
Study, and Immunohistochemistry
Table 1 summarizes key proteomic results (further details in the 
Supplementary Materials, available online). Data were collected 
for 1292 2D-DIGE–resolved gel spots for comparative analyses. 
Principal components analysis demonstrated clustering of cell 
types with parental control cells separated from metastatic 
cell types. Bone metastatic variants clustered separately from 
parental cells and from lung metastatic variants, indicating that 
differences from parental cells are organ specific and not simply 
a general metastatic effect. Nearly 1000 gel spots demonstrated 
evidence of differential protein expression between cell types (P 
< .05, Kruskal-Wallis test [18]). In order to isolate gel spots with 
the most robust and statistically significant differential expres-
sion, stringent selection and filtering criteria were used (see the 
Supplementary Materials, available online). A  list of 32 DIGE 
spots was determined, returning 75 unique protein identifica-
tions where fold changes were 2 or greater (P = .029, Wilcoxon-
Mann-Whitney test). We focused on the eight of these proteins 
that were statistically significantly upregulated in the BM cell 
lines only. These were then assessed on the basis of highest con-
fidence in identification by mass spectrometry and/or likely rel-
evance to breast cancer and/or bone metastasis using published 
literature (see Table 1), and the expression of proteins selected 
on this basis was tested directly in BM1 and BM2 cells using 
western blotting (Figure  2). These were: macrophage-capping 
protein (CAPG); PDZ domain-containing protein GIPC1 (GIPC1); 
and transcriptional activator protein Pur-alpha (PURA). Western 
blotting showed that CAPG, GIPC1, and PURA antibodies (see 
Supplementary Table 9, available online) detected single bands 
(at the appropriate molecular weight for their respective anti-
gens), demonstrating their specificity. Figure 2 shows that CAPG 
and GIPC1 (but not PURA – data not shown) were verified as hav-
ing higher expression in BM cell lysates, and on this basis CAPG 
and GIPC1 were selected for clinical validation.
The CAPG and GIPC1 antibodies were then subsequently 
used for immunohistochemistry. The CAPG antibody is for-
mally certified for immunohistochemistry (IHC) application (see 
Supplementary Table 9, available online). While the Abcam GIPC1 
antibody is not formally certified, this is not unusual for some 
antibodies and in our hands it performed well under formalin-
fixed, paraffin-embedded–IHC conditions. A single specific band 
at the appropriate molecular weight for GIPC1 was detected in 
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WB analysis of cell lysates (36kDa) (Figure  2), providing confi-
dence that the antibody is robust. Each antibody showed a wide 
range of cytoplasmic staining intensity in the graded breast 
cancer TMAs (see Supplementary Materials, available online), 
demonstrating appropriate antibody sensitivity. TMAs for the 
training and validation sets were stained a few months apart 
using antibodies from the same supplier, though for GIPC1 from 
two batches (lots). Nevertheless, identical staining profiles were 
Table 1. Summary of key proteomic results*
DIGE
spot#
Fold
change
K-W
P Entry Entry name Protein name Gene
Relevance to
breast cancer and/or bone  
metastasis
751 2.2 .0039 P17987 TCPA_HUMAN T-complex protein 1 subunit 
alpha
TCP1 Little or no relevant literature
904 2.0 .0028 P31943 HNRH1_HUMAN Heterogeneous nuclear  
ribonucleoprotein H  
(hnRNP H)
HNRNPH1 Some literature, but not strong 
relevance (31)
904 2.0 .0028 Q96KP4 CNDP2_HUMAN Cytosolic-nonspecific  
dipeptidase (EC 3.4.13.18)
CNDP2 Little or no relevant literature
1106 2.5 .0034 P06132 DCUP_HUMAN Uroporphyrinogen  
decarboxylase (EC 4.1.1.37)
UROD Some literature, but not strong 
relevance (32)
1106 2.5 .0034 P40121 CAPG_HUMAN Macrophage-capping protein CAPG Significant relevant literature (33,34)
1106 2.5 .0034 P53365 ARFP2_HUMAN Arfaptin-2 ARFIP2 Little or no relevant literature
1106 2.5 .0034 Q00577 PURA_HUMAN Transcriptional activator 
protein Pur-alpha
PURA Little or no relevant literature
1158 2.0 .0042 O14908 GIPC1_HUMAN PDZ domain–containing  
protein GIPC1
GIPC1 Significant relevant literature 
(27,35–37)
* “Fold change” refers to the average of the relevant pair-wise comparisons possible within the dataset. Of the original 75 proteins identified with statistically signifi-
cant fold changes, eight were upregulated in BM cells only (and no other cells) as shown in the table. These eight proteins were selected for further consideration by 
looking for literature evidence of relevance to breast cancer and/or bone metastasis as indicated in the table. K-W P value refers to the Kruskal-Wallis nonparametric 
analysis of variance test. Entry details from Universal Protein Resource (UniProt) tags are also shown. (NB multiple protein identifications from one two-dimensional 
gel electrophoresis spot are common.) DIGE = difference gel electrophoresis.
Figure 2. Macrophage-capping protein (CAPG) and PDZ domain–containing protein GIPC1 (GIPC1) protein expression in cells and patient breast cancer tissue. Left 
hand panel shows western blot verification of high CAPG and GIPC1 protein expression in BM1 and BM2 cell lysates compared with parental cells (expression changes 
>2-fold with P < .03, by Student’s t test); upper part shows blot expression with loading control. Data are means ± SD. Right hand panel illustrates examples of dif-
ferential protein expression in AZURE tissue microarray breast tumor cores for CAPG and GIPC1. In each case, the antibody localization has been used in conjunction 
with diaminobenzidine (DAB; brown), and the scoring is based on the intensity of staining in the cytoplasmic compartment in the tumor cells only. Scale bar = 200 µm. 
CAPG = macrophage-capping protein; GIPC1 = PDZ domain–containing protein GIPC1; PCC = MDA-MB-231 cells.
J. A. Westbrook et al. | 5 of 10
a
r
t
ic
le
Table 2. Characteristics of the patients whose tissue was assessed on TMAs in this study (as at baseline on the AZURE study) and first disease-
free survival events
Characteristic
Training set Validation set Combined sets
Full AZURE trial  
population
Zoledronate
(n = 216)
Control
(n = 211)
Zoledronate
(n = 147)
Control
(n = 150)
Zoledronate
(n = 363)
Control
(n = 361)
Zoledronate
(N = 1681)
Control
(n = 1678)
Age, median (range), y 51 (26–75) 51 (33–79) 50 (26–77) 52 (33–79) 50 (26–77) 52 (33–79) 51 (20–87) 51 (21–89)
Axillary lymph nodes, No. (%)
 0 1 (0.5) 4 (1.9) 1 (0.7) 1 (0.7) 2 (0.6) 5 (1.4) 30 (1.8) 32 (1.9)
 1–3 140 (64.8) 147 (69.7) 107 (72.8) 96 (64.0) 247 (68.0) 243 (67.3) 1042 (62.0) 1033 (61.6)
 ≥4 75 (34.7) 60 (28.4) 39 (26.5) 53 (35.3) 114 (31.4) 113 (31.3) 604 (35.9) 607 (36.2)
Tumor stage, No. (%)
 T1 73 (33.8) 80 (37.9) 55 (37.4) 58 (38.7) 128 (35.3) 138 (38.2) 542 (32.2) 523 (31.2)
 T2 117 (54.2) 98 (46.4) 76 (51.7) 77 (51.3) 193 (53.2) 175 (48.5) 850 (50.6) 867 (51.7)
 T3 20 (9.3) 29 (13.7) 12 (8.2) 14 (9.3) 32 (8.8) 43 (11.9) 228 (13.6) 228 (13.6)
 T4 6 (2.8) 4 (1.9) 4 (2.7) 1 (0.7) 10 (2.8) 5 (1.4) 58 (3.5) 59 (3.5)
Histological grade, No. (%)
 1 14 (6.5) 16 (7.6) 14 (9.5) 22 (14.7) 28 (7.7) 38 (10.5) 145 (8.6) 140 (8.3)
 2 85 (39.4) 85 (40.3) 53 (36.1) 61 (40.7) 138 (38.0) 146 (40.4) 731 (43.5) 708 (42.2)
 3 115 (53.2) 108 (51.2) 79 (53.7) 66 (44.0) 194 (53.4) 174 (48.2) 765 (45.5) 787 (46.9)
ER status, No. (%)
 ER positive 160 (74.1) 170 (80.6) 118 (80.3) 119 (79.3) 278 (76.6) 289 (80.1) 1319 (78.5) 1316 (78.4)
 ER negative 55 (25.5) 38 (18.0) 29 (19.7) 31 (20.7) 84 (23.1) 69 (19.1) 349 (20.8) 355 (21.2)
 ER unknown 1 (0.50) 3 (1.4) 0 (0.0) 0 (0.0) 1 (0.3) 3 (0.8) 13 (0.8) 7 (0.4)
PR status, No. (%)
 PR positive 71 (32.9) 62 (29.4) 60 (40.8) 56 (37.3) 131 (36.1) 118 (32.7) 725 (43.1) 698 (41.6)
 PR negative 37 (17.1) 40 (1908) 26 (17.7) 36 (24.0) 63 (17.4) 76 (21.1) 382 (22.7) 424 (25.3)
 PR unknown 107 (49.5) 108 (51.2) 61 (41.5) 58 (38.7) 168 (46.3) 166 (46.0) 571 (34.0) 548 (32.7)
HER2 status, No. (%)
 HER2 positive 27 (12.5) 33 (15.6) 14 (9.5) 13 (8.7) 41 (11.3) 46 (12.7) 192 (11.4) 223 (13.3)
 HER2 negative 60 (27.8) 54 (25.6) 52 (35.4) 40 (26.7) 112 (30.9) 94 (26.0) 648 (38.5) 603 (35.9)
 HER2 unknown/not measured 129 (59.7) 124 (58.8) 81 (55.1) 97 (64.7) 210 (57.9) 221 (61.2) 831 (49.5) 841 (50.1)
Menopausal status, No. (%)
 Pre-menopausal 94 (43.5) 94 (44.5) 69 (46.9) 60 (40.0) 163 (44.9) 154 (42.7) 751 (44.7) 753 (44.9)
 ≤ 5 years since menopause 32 (14.8) 38 (18.0) 19 (12.9) 22 (14.7) 51 (14.0) 60 (16.6) 247 (14.7) 243 (14.5)
 > 5 years since menopause 74 (34.3) 57 (27.0) 45 (30.6) 56 (37.3) 119 (32.8) 113 (31.3) 519 (30.9) 522 (31.1)
 Menopausal status unknown 16 (7.4) 22 (10.4) 14 (9.5) 12 (8.0) 30 (8.3) 34 (9.4) 164 (9.8) 160 (9.5)
Planned systemic  
therapy, No. (%)
 Endocrine therapy alone 18 (8.3) 13 (6.2) 6 (4.1) 7 (4.7) 24 (6.6) 20 (5.5) 76 (4.5) 76 (4.5)
 Chemotherapy alone 56 (25.9) 42 (19.9) 25 (17.0) 30 (20.0) 81 (22.3) 72 (19.9) 361 (21.3) 358 (21.3)
 Endocrine therapy plus  
 chemotherapy
142 (65.7) 156 (73.9) 116 (78.9) 113 (75.3) 258 (71.1) 269 (74.5) 1244 (74.0) 1244 (74.1)
Type of chemotherapy, No. (%)
 Anthracyclins 194 (89.8) 193 (91.5) 134 (91.2) 139 (92.7) 328 (90.4) 332 (92.0) 1568 (97.7) 1564 (97.6)
 Taxanes 35 (16.2) 29 (13.7) 14 (9.5) 15 (10.0) 49 (13.5) 44 (12.2) 390 (24.3) 385 (24.0)
Timing of chemotherapy
 Neo-adjuvant 7 (3.2) 5 (2.4) 2 (1.4) 3 (2.0) 9 (2.5) 8 (2.2) 103 (6.5) 104 (6.5)
 Postoperative 209 (96.8) 206 (97.6) 145 (98.6) 147 (98.0) 354 (97.5) 353 (97.8) 1502 (93.6) 1498 (93.5)
Statin use, No. (%) 9 (4.2) 9 (4.3) 7 (4.8) 8 (5.3) 16 (4.4) 17 (4.7) 97 (5.8) 100 (6.0)
Type of first disease-free survival 
event, No. (%)
 Loco-regional recurrence 16 (7.4) 10 (4.7) 12 (8.2) 5 (3.3) 28 (7.7) 15 (4.2) 79 (4.7) 78 (4.7)
 Distant recurrence 41 (19) 44 (20.9) 21 (14.3) 32 (21.3) 62 (17.1) 76 (21.1) 332 (19.8) 341 (20.3)
 Distant and loco-regional  
 recurrence
5 (2.3) 2 (0.9) 0 (0) 1 (0.7) 5 (1.4) 3 (0.8) 18 (1.1) 21 (1.3)
 Death without prior  
 recurrence
6 (2.8) 9 (4.3) 1 (0.7) 3 (2) 7 (1.9) 12 (3.3) 44 (2.6) 53 (3.2)
First distant recurrence is  
nonskeletal, No. (%)
31 (14.4) 18 (8.5) 10 (6.8) 17 (11.3) 41 (11.3) 35 (9.7) 194 (11.5) 165 (9.8)
First distant recurrence is  
skeletal and other, No. (%)
15 (6.9) 28 (13.3) 11 (7.5) 16 (10.7) 26 (7.2) 44 (12.2) 156 (9.3) 197 (11.7)
First distant recurrence is  
skeletal only, No. (%)*
7 (3.2) 22 (10.4) 11 (7.5) 9 (6) 18 (5) 31 (8.6) 97 (5.8) 140 (8.3)
* This group is a subset of those classified as skeletal and other, where skeletal recurrences were the only first distant recurrences.
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observed for both TMA sets, which were validated by a spe-
cialist breast histopathologist (AMH), providing confidence on 
reproducibility.
Patients
We initially explored associations between clinical outcomes and 
TMA immunohistochemistry scores for CAPG and GIPC1 (pri-
mary antibodies from Sigma HPA019080, rabbit IgG, and abcam 
ab89684, mouse IgG, respectively) in a training set of 427 ran-
domly assigned AZURE trial patients (211 control, 216 zoledro-
nate). A  second independent validation set from 297 randomly 
assigned AZURE trial patients (147 control, 150 zoledronate) was 
available for confirmation of findings from the training set. There 
was a high level of agreement between the two independent 
scorers as judged by Cohen’s kappa score (overall, κ = 0.85 and 
κ = 0.80 for CAPG and GIPC1, respectively). Table 2 displays the 
patient characteristics of both training and validation sets and 
the combined sets and shows that these are similar to those of 
the overall AZURE population. In association analyses, neither 
CAPG nor GIPC1 expression showed any statistical association 
with baseline variables (eg, age, lymph node involvement, ER 
status, menopausal status, systemic therapy, chemotherapy, and 
statin use) (see Supplementary Tables 1, 2, and 3, available online).
Association of CAPG and GIPC1 With Skeletal 
Metastasis
Training Set
Analysis of the control arm data suggested that patients with 
high CAPG and GIPC1 scores (CAPGhi/GIPC1hi) had an increased 
risk of developing distant skeletal events. Figure  3 shows that 
when either CAPG or GIPC1 is high the risk of developing a dis-
tant skeletal event is greater than when both scores are low and 
that patients who are CAPGhi/GIPC1hi have the greatest risk. This 
is true whether the first distant recurrence event recorded was 
in bone alone or skeletal plus another distant site (skeletal and 
other). These data led to analyses considering the potential bio-
markers individually and also as a simple bivariate score, where 
the number of high protein expressions is summed on a scale of 0 
to 2, (ie, 0 = both low; 1 = one low, one high; 2 = both high). Results 
from these analyses confirm that in the control arm CAPG and 
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Figure 3. Control arm of the AZURE trial population. Kaplan-Meier estimates of the survival function showing association between protein expression and time to first 
distant recurrences (DRs). Upper left) Training set; first DR is skeletal only. Upper right) Training set; first DR includes skeletal as well as other distant site(s). Lower left) 
Validation set; first DR is skeletal only. Lower right) Validation set; first DR includes skeletal as well as other distant site(s). High indicates a tissue microarray (TMA) score 
of 3. Low indicates TMA score of 1 or 2. P values refer to the two-sided log-rank test. CAPG = macrophage-capping protein; GIPC1 = PDZ domain–containing protein GIPC1.
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GIPC1 independently have prognostic potential as biomarkers 
for development of bone metastasis, CAPG showing a weak asso-
ciation and GIPC1 a stronger association with bone-only metas-
tasis (Supplementary Tables 4 and 5, available online). However, 
Figure 3 and Table 3 show that this prognostic potential for bone-
only metastasis as first distant event is strongly enhanced when 
both CAPG and GIPC1 are high, treated as a simple bivariate score 
(HR = 3.50, 95% CI = 1.48 to 8.32, P = .004), and this also extends to 
patients where both skeletal and other distant recurrences are 
recorded as first event. Such associations were not observed in 
distant events not involving the skeleton (Table 3).
Importantly, statistically significant associations of a high 
bivariate score with events involving the skeleton were not seen 
in the corresponding group of patients who received zoledro-
nate (Table 3), indicating a potential predictive effect for treat-
ment response (eg, for skeletal only, HR = 1.28, 95% CI = 0.14 to 
11.49, P = .823).
Validation Set
It was prespecified that for the primary analysis this second set 
would independently validate the results observed in the train-
ing set if the P value for the bivariate score was less than .05 
for the Cox proportional hazards regression approach, described 
in the Methods section. As shown in Table 3, these analyses for 
skeletal events only (P  =  .011) and skeletal and other events 
(P = .037) did indeed independently validate the bivariate score 
as a prognostic biomarker for bone metastasis (further data 
shown in Supplementary Tables 4 and 5, available online).
Combination of Training and Validation Sets
We have carried out further analyses using the greater power 
obtained by combining the training and validation sets, which 
correspond to 571 patients scored for both proteins (Table 3). For 
the control arm, Figure 4 demonstrates the increased power deliv-
ered by this large combined dataset, confirming that the compos-
ite biomarker CAPGhi/GIPC1hi is a highly statistically significant 
prognostic biomarker for distant recurrence events involving the 
skeleton. Notably, even with the increased power, there was no 
statistically significant association of the markers with nonskel-
etal metastases in either control or zoledronate arms (Table 3). 
The combined set also confirms the advantage of the combined 
bivariate score over either CAPG or GIPC1 individually, as demon-
strated by the increased hazard ratio values; eg, for skeletal only 
events, the hazard ratio was 4.54 (95% CI = 2.11 to 9.78, P < .001) in 
the bivariate score (Table 3), compared with 2.92 (95% CI = 1.51 to 
5.65, P = .001) for GIPC1 and 2.31 (95% CI = 1.14 to 4.69, P = .020) for 
CAPG (Supplementary Tables 4 and 5, available online).
We also considered an alternative cutpoint, ie high vs low 
between scores of 1 and 2, rather than between scores 2 and 
3.  This led to very similar results in terms of direction of the 
effects, and statistical significance and the corresponding 
version of Figure  4 for this alternative cutpoint is shown in 
Supplementary Figure 3 (available online).
Supplementary Tables 6 and 7 and Supplementary Figure 1 
(available online) also show that the composite biomarker is 
similarly prognostic for distant recurrence events involving the 
skeleton when divided into pre/perimenopausal and postmeno-
pausal patient groups.
Prediction of Treatment Benefit
The effectiveness of zoledronate in reducing the risk of bone 
metastases in patients that are CAPGhi/GIPC1hi is highlighted in 
Figure 5, while zoledronate has no statistically significant effect 
in reducing occurrence of nonskeletal metastases. For example, T
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CAPGhi/GIPC1hi patients on zoledronate have a 90% reduced haz-
ard of a skeletal-only distant recurrence (adjusted HR = 0.10, 95% 
CI = 0.01 to 0.81, P = .008) as compared with patients on stand-
ard therapy; whereas when both CAPG and GIPC1 are not high, 
patients on zoledronate have a 9% reduced hazard of a skele-
tal-only distant recurrence (adjusted HR  =  0.91, 95% CI  =  0.43 
to 1.90), with significant heterogeneity in effect between these 
subgroups (P = .013, interaction test). This suggests that CAPGhi/
GIPC1hi patients attain approximately a 10-fold increase in treat-
ment benefit.
Similar effects are observed for time to skeletal and other 
distant recurrence (Figure 5), and a similar trend to benefit in 
CAPGhi/GIPC1hi patients is observed in analysis of time to first 
skeletal event irrespective of other recurrences (P  =  .128). The 
potential predictive effect of the composite biomarker may also 
be clearly seen in plots of zoledronate vs control for patients 
with CAPGhi/GIPC1hi and patients who do not have CAPGhi/
GIPC1hi (Supplementary Figure 4, available online).
Overall Survival
Based on the combined dataset, CAPGhi/GIPC1hi patients in the 
control arm experienced statistically significantly shorter OS, 
with a five-year survival of 76.2% (95% CI = 64.4 to 90.3), compared 
with patients for whom both GIPC1 and CAPG were not high, 
with a five-year survival of 85.9 (95% CI = 81.7 to 90.4) (HR = 1.81, 
Figure 4. Combined sets. Kaplan-Meier estimates of the survival function for time to distant recurrence and overall survival for control and zoledronate arms. High 
signifies both macrophage-capping protein (CAPG) and PDZ domain–containing protein GIPC1 (GIPC1) high; low signifies other combinations where not both CAPG and 
GIPC1 are high. A and B) Skeletal only; first distant recurrence only skeletal. C and D) Skeletal and other; first report of distant recurrence included skeletal and other 
site(s) of metastasis. E and F) Nonskeletal; first distant recurrence does not contain any skeletal component. G and H) First skeletal recurrence irrespective of timing 
and sites of local and nonskeletal recurrences. I and J) Overall survival. P values refer to the two-sided log-rank test. DR = distant recurrence; OS = overall survival.
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95% CI = 1.01 to 3.24, P = .045) (Figure 4; Supplementary Table 8, 
available online). In the zoledronate arm, the corresponding fig-
ures for five-year survival were 82.3% (95% CI = 77.6, to 87.3) and 
88.2% (95% CI = 78.0 to 99.8) (HR = 0.71, 95% CI = 0.32 to 1.55, 
P =  .385), suggesting a treatment benefit of approximately 2.5-
fold (comparison of HR values). The corresponding adjusted haz-
ard ratio value (Figure 5) was 0.63 (95% CI = 0.25 to 1.6, P = .199).
Discussion
In this study, we found that a composite biomarker comprising 
CAPG and GIPC1 in primary breast tumor tissue was not only 
associated with subsequent development of bone metastasis 
and reduced survival but was also predictive of the treatment 
benefits of adjuvant zoledronate. We believe this is the first such 
validated biomarker to be reported and consequently could be 
considered for assessment of individual patient risk and selec-
tion of patients for adjuvant bisphosphonate treatment. It 
should be emphasised that even with the increased power of the 
combined datasets we found no associations between the com-
posite biomarker and development of nonskeletal metastases, 
further emphasising the specificity of this biomarker for devel-
opment of bone metastases. This clinical finding also appears 
to justify our strategy of only taking forward proteomic-derived 
candidate biomarker proteins upregulated in BM1 and BM2 cells 
but not in LM cells.
CAPG is a calcium-sensitive, actin-binding protein that plays 
a role in regulating cytoplasmic and nuclear structures, reported 
to modify cell migration and invasion (19). High expression of 
CAPG has been associated with progression and/or metasta-
sis of a range of tumors (20–24) and has been demonstrated 
in breast cancer cells with increased metastatic potential (6). 
A recent study has demonstrated that CAPG inhibition reduces 
breast cancer metastasis in a murine model (25). GIPC1 is a cyto-
plasmic protein that also localizes to the peripheral membrane, 
acting as an adaptor protein linking receptor interactions to 
intracellular signaling pathways, including cell cycle regulation, 
and expression has been associated with some cancers (26). 
Overexpression of GIPC1 has been associated with breast tumors 
(27), and silencing of GIPC1 in MDA-MB-231 breast cancer cells 
leads to increased apoptotic death, G2 cell cycle arrest, modified 
cell adhesion, and migration (28). Key proteins of breast cancer 
progression (including the Akt/Mdm2/p53 axis and IGF-1) are 
downstream of GIPC1 signaling (10). To date, neither CAPG nor 
GIPC1 appear to have been studied specifically in the context of 
breast cancer bone metastasis.
Bone metastatic variants of human breast cancer cell lines, 
principally MDA-MB-231, have been used to identify proteins 
important in defining breast cancer metastasis, eg, the role 
of noggin (29). Also, a comparison of primary breast and bone 
metastatic tissue with an osteotropic MDA-MB-231 cell line 
showed a high degree of convergence for proteins up- or down-
regulated (30), thus validating such cell models. However, our 
study appears to be the first to fully validate candidates from 
cell lines in patient tissue prospectively collected for such a pur-
pose, associated with high-quality clinical data. Further stud-
ies to elucidate the biological mechanisms through which CAPG 
and GIPC1 are implicated in bone metastasis development and 
the effects of antibone resorptive agents on these processes are 
currently underway in our laboratories.
There are several limitations to this study. TMAs were 
not available from the whole of the AZURE patient cohort, 
though the numbers available for analysis and the statistical 
power achieved suggest that this is not a serious limitation. 
Although our study has clearly demonstrated the value of 
the composite biomarker CAPGhi/GIPC1hi in both univariate 
and multivariable analyses, it would be possible in future 
analyses to explore whether the addition of other novel bio-
markers could further enhance prognostic and predictive 
ability.
The poorer OS in CAPGhi/GIPC1hi patients is especially strik-
ing and is presumably driven by the as-yet unidentified role of 
these proteins in promoting bone metastasis. However, because 
of the zoledronate treatment effect observed in the current 
study (with HR reduction of up to 10-fold for bone metastases 
and 2.5-fold for death in CAPGhi/GIPC1hi patients) and the res-
toration of these risks to that of the rest of the breast cancer 
population studied, the composite biomarker CAPGhi/GIPC1hi 
may have an important future role in the selection of patients 
most likely to benefit from adjuvant antiresorptive treatment 
and for stratification in further trials, given that zoledronate has 
a significant toxicity profile, including osteonecrosis of the jaw 
in a small proportion of patients.
Future study of this composite biomarker if samples from 
further datasets become available would be useful and could 
also enable assessment of whether this biomarker benefit was 
restricted to zoledronate or applies also to other bone-targeted 
agents such as clodronate or denosumab.
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Figure 5. Forest plot showing effect of zoledronate in subgroups defined by the bivariate score composed of macrophage-capping protein and PDZ domain–containing 
protein GIPC1 in relationship to time to distant recurrence events and overall survival. Skeletal only (first distant recurrence event only skeletal); skeletal and other (first 
distant recurrence event reported includes skeletal and other site[s] of metastasis); nonskeletal (first distant recurrence event does not include skeletal recurrence); 
first skeletal (first skeletal event irrespective of whether other distant events have occurred first). All hazard ratios are adjusted for systemic therapy plan, estrogen 
receptor status, and lymph node involvement. Hazards ratios of less than 1 indicate improvement with zoledronate. CI = confidence interval; HR = hazard ratio.
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